Related Experiment Video

Updated: Oct 9, 2026

Quantitative Immunoblotting of Cell Lines as a Standard to Validate Immunofluorescence for Quantifying Biomarker Proteins in Routine Tissue Samples
09:58

Quantitative Immunoblotting of Cell Lines as a Standard to Validate Immunofluorescence for Quantifying Biomarker Proteins in Routine Tissue Samples

Published on: January 7, 2019

[Fas mediated apoptosis inhibited by human bcl-2 gene in lymphoma cell line Jurkat]

H Cao1, Q Qian, M Wu

  • 1Tumor Immunology and Gene Therapy Center, Eastern Institute of Hepatobiliary Surgery, Shanghai 200433.

Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi
|March 13, 2001
PubMed
Abstract

Insights

The BCL-2 gene helps lymphoma cells evade immune detection by blocking apoptosis, a key process in cancer development. This finding sheds light on how cancer cells survive immune responses.

Area of Science:

  • Molecular Biology
  • Immunology
  • Oncology

Background:

  • Lymphoma development involves complex mechanisms of immune evasion.
  • Understanding how cancer cells escape immune surveillance is crucial for developing effective therapies.

Purpose of the Study:

  • To investigate the role of the BCL-2 gene in lymphoma's immune surveillance evasion.
  • To elucidate the mechanism by which BCL-2 contributes to lymphoma pathogenesis.

Main Methods:

  • Constructed a recombinant retroviral vector (pLXSN-bcl-2) for BCL-2 gene transfer.
  • Transfected human lymphoma Jurkat cells and selected for stable expression.
  • Induced apoptosis using anti-Fas monoclonal antibody to mimic T-cell cytotoxic activity.

Main Results:

  • BCL-2 gene expression was significantly upregulated in transfected Jurkat cells.
  • Fas gene expression remained unchanged.
  • Apoptosis induction by anti-Fas antibody was inhibited in Jurkat cells overexpressing BCL-2.

Conclusions:

  • Overexpression of BCL-2 inhibits Fas-mediated apoptosis in lymphoma cells.
  • BCL-2 contributes to lymphoma immune evasion by preventing programmed cell death.
  • Targeting BCL-2 may offer a therapeutic strategy for lymphoma.

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...